MedTrace Logo

Ga-68-NODAGA-MJ9 Compared to F-18-FCH PET/CT for Prostate Cancer Patients

NCT02111954 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2017-05-23

No results posted yet for this study

Summary

Prostate cancer patients for whom a F-18-FCH PET/CT is indicated. Ga-68-NODAGA-MJ9 is a new PET/CT radiotracer aiming at giving complementary information : more precise images and early localisation of recurrence to standard imaging

Conditions

Interventions

DIAGNOSTIC_TEST

1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9

Each patient will have two PET/CT

Sponsors & Collaborators

  • University of Lausanne Hospitals

    lead OTHER

Principal Investigators

  • John O. Prior, MD, PhD · University of Lausanne Hospitals

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-10-28
Completion
2016-10-28

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02111954 on ClinicalTrials.gov